EBS - Why Emergent BioSolutions Slipped on Friday
Shareholders of vaccine and antibody therapy specialist Emergent BioSolutions (NYSE: EBS) were feeling a bit queasy on Friday afternoon. That day, the company's stock fell by almost 4.9% after the release of the latest quarterly earnings.
In its fiscal third quarter of 2020, Emergent BioSolutions enjoyed 24% year-over-year growth in total revenue, which landed at $385.2 million. Meanwhile, the company's non- GAAP (adjusted) net income nearly doubled to $119 million ($2.19 per share).
Image source: Getty Images.
For further details see:
Why Emergent BioSolutions Slipped on Friday